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Dear Editor 
 
We describe a case of systemic listeriosis during a phase I trial of ADXS11-001 
(axalimogene filolisbac) in Human papillomavirus (HPV)-positive oropharyngeal 
cancer (OPC).  
 
ADXS11-011 is a novel therapeutic vaccine under investigation in HPV-associated 
malignancies1. ADXS11-001 is a live, bioengineered Listeria monocytogenes (Lm) 
vector containing a plasmid insert (pGG55) which, inter alia, facilitates secretion of 
HPV genotype-16 (HPV-16) E7 oncoprotein fused to an attenuated Lm virulence 
factor, Listeriolysin O. ADXS11-001 induces immune responses in HPV-related 
cancers through multiple mechanisms of action 1, 2. 
 
Clinical testing of ADXS11-001 is most advanced in cervical cancer1, in which HPV-
16 has a causal role3. HPV-16 is associated with other malignancies, including OPC, 
in which there has recently been a rapid rise in incidence. Although HPV-related 
OPC is usually cured following multi-modality treatment, a not insignificant number of 
patients develop recurrent/metastatic disease. In addition, current standard-of-care 
treatments have long-term functional consequences with negative impact on quality-
of-life. Therefore, novel therapeutic agents that will improve survival and/or reduce 
the incidence of adverse events are urgently needed. Following encouraging data 
from trials in cervical cancer, we initiated a dose-escalation phase I trial of ADXS11-
001 in patients treated with curative intent for locally-advanced HPV-16-positive OPC 
(REALISTIC - NCT01598792), the primary endpoint of which was to establish the 
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safety and toxicity  profile of the vaccine in this clinical setting. 
(https://clinicaltrials.gov). 
 
Patient 1 was enrolled in October 2013, and received two vaccinations at dose-level 
1 (3.3x108 colony-forming units (CFU)) without unexpected adverse effects. Patient 2 
was a 61 year old man with a past history of treated hypertension and 
hypercholesterolemia. He had undergone transoral laser surgery, followed by post-
operative radiotherapy, for T2N2aM0 OPC 16.5 months previously. His ECOG 
performance status was 0 on trial entry. 
 
Approximately 3.5 hours after intravenous (iv) administration of 3.3x108 CFU 
ADXS11-001, he developed headache and generalised flu-like symptoms, although 
all observations were normal. Acetaminophen (1g) was given iv with clinical benefit. 
Similar symptoms, with normal observations, recurred at 6.5 hours post-infusion and 
resolved with 1g iv acetaminophen. At 8.5 hours post-infusion, the patient became 
unwell and pyrexial (38.1°C) with a tachycardia (93 bpm). Symptoms failed to settle 
with further acetaminophen and he became nauseated and vomited. Over the next 6 
hours, symptoms and vital signs, whilst fluctuating, were within the range expected 
from previous safety data and were controlled by conservative measures 
(acetaminophen, ondansetron).   
 
At 14.5 hours post-vaccination his clinical condition deteriorated significantly, with 
pyrexia (39.1°C), tachycardia (106 bpm) and profound nausea/vomiting. At this point, 
per protocol,  2g iv ampicillin QDS and iv fluids were initiated and he was transferred 
to the Infectious Disease Unit (IDU). Clinical examination and investigations revealed 
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left basal pneumonia. Sequential blood tests confirmed elevated alanine 
aminotransferase (ALT) and gamma glutamyl transpeptidase (ɣGT), peaking at 131 
U/L (NR: 7-55U/L) and 256 U/L (NR: 0-45 U/L), respectively, on day 7 post-
vaccination. The patient's condition improved and he was fit for discharge 7 days 
after admission to the IDU. Liver enzymes returned to normal over several weeks. 
 
Per protocol, blood was taken for culture 5 hours post-vaccination and was negative 
for bacterial growth after 72 hours. However, repeat blood culture, immediately 
before institution of antibiotics, grew Listeria monocytogenes with identical antibiotic 
resistance to ADXS11-001 (chloramphenicol resistance conferred by pGG55 plasmid 
insert). Four subsequent blood cultures and a stool test were negative for Listeria 
monocytogenes. Chest radiograph after discharge was clear. cANCA/pANCA were 
negative, Ig profile was normal and there was no paraprotein on electrophoresis. 
Importantly, the patient has had no recurrence of symptoms since discharge and 
remains well 20 months post-vaccination with ADXS11-001. 
 
Following this serious adverse event, the trial was immediately put on hold.  
Following consultation with the vaccine manufacturer (Advaxis), the trial was 
terminated early. To our knowledge, no other cases of listeriosis have been reported 
following ADXS11-001.  
 
Although we did not confirm sequence identity between the pathogen grown at blood 
culture and ADXS11-001, the chronology of events and pattern of antibiotic 
resistance point to the fact that systemic listeriosis was caused by the study drug. 
Internal review of the temperature log of the freezer where vaccine was stored 
D
ow
nl
oa
de
d 
by
 [T
err
y J
on
es
] a
t 0
4:0
7 1
3 D
ec
em
be
r 2
01
5 
 5 
 
confirmed several minor temperature excursions (highest temperature -52°C for 20 
minutes) in the period before vaccination. An internal enquiry undertaken by the 
sponsors and accepted by the UK Medicines and Healthcare Regulatory Agency, 
found no relationship between the temperature deviations and the occurrence of 
systemic listeriosis.  
 
In conclusion, we highlight a potential adverse event of attenuated Lm vectors and 
urge caution on the part of investigators working with such agents.   
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